Gufic BioSciences Ltd
Gufic BioSciences Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
The company targets a minimum 15% growth in sales/revenue for FY 2026-27 and FY 2027-28, with an optimistic aim of up to 20% or more depending on regulatory approvals and market factors. FY '27 revenue growth targeted at a minimum of 15%, with potential to reach 20% or more depending on regulatory approvals and market factors (Page 14, 6).
From Gufic BioSciences Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- The company targets a minimum 15% growth in sales/revenue for FY 2026-27 and FY 2027-28, with an optimistic aim of up to 20% or more depending on regulatory approvals and market factors.
- International business (exports) is expected to ramp up notably from Q2/Q3 FY 2026 with the completion of audits and approvals (e.g., EU GMP certificate by March/April 2026).
- The Indore plant ramp-up will contribute significantly, with production utilization projected to hit 50% by Q4 FY 2026-27 and further growth thereafter.
- Export revenues from Indore are expected to start materializing in Q3/Q4 FY 2026, especially across Europe, Southeast Asia, and regulated markets.
- Domestic branded business growth is seen around 8% due to correction in debtor control and divestment in certain divisions.
2 more points from Gufic BioSciences Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Gufic BioSciences Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Investment in Selvax, a cancer vaccine therapy for solid tumors, with over $150,000 invested over the last 4-5 years; this is a long-term, start-up-like investment with promising animal-level proof of concept and ongoing progress such as outsourcing final construct to Syngene.
- Indore plant expansion with term loans taken for capacity ramp-up; expected to reach 50% utilization by Q4 FY '26-'27 and contribute to export revenue starting Q3/Q4 FY '26.
- Investments in technology transfer projects like GLP-1 validation batches at Indore, enhancing production capabilities.
- Implementation of Marg software in stockists to strengthen data control and optimize working capital.
2 more points from Gufic BioSciences Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Gufic BioSciences Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The current order book at Indore (Unit-2) stands at around INR150 crores to INR155 crores.
- Management aims to reduce this order book to around INR80 crores to INR90 crores.
- The reduction target is to bring the order book from a 90-day window to a 60-day window.
- Navsari orders for exports to countries like the U.K., Portugal, and Brazil are also ramping up.
- The export division has shown growth of approximately 40%, though the base is smaller (~INR120 crores).
2 more points from Gufic BioSciences Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Gufic BioSciences Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q3 FY26): revenue ₹231 Cr, net profit ₹12 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Gufic BioSciences Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Natural Capsules (Q3 FY26)
Q3FY26 revenue from operations: ₹37.75 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q3 FY26 investor presentation — and how it ranks
- Wanbury (Q3 FY26)
Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against
- Gujarat Themis Biosyn Ltd (Q3 FY26)
43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against
- Balaxi Pharma (Q3 FY26)
Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Key investor presentation takeaways from Balaxi Pharma's Q3 FY2
Arthneeti Pro · Annual
Gufic BioSciences Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Gufic BioSciences Ltd Q3 FY26 results?
The company targets a minimum 15% growth in sales/revenue for FY 2026-27 and FY 2027-28, with an optimistic aim of up to 20% or more depending on regulatory approvals and market factors. FY '27 revenue growth targeted at a minimum of 15%, with potential to reach 20% or more depending on regulatory approvals and market factors (Page 14, 6).
What is Gufic BioSciences Ltd share price analysis?
Gufic BioSciences Ltd currently shows a neutral. The stock trades at a P/E of 62.6 with a market cap of ₹3,955 Cr. Investors should review the full earnings analysis for detailed insights.
Is Gufic BioSciences Ltd planning capital expenditure?
Investment in Selvax, a cancer vaccine therapy for solid tumors, with over $150,000 invested over the last 4-5 years; this is a long-term, start-up-like investment with promising animal-level proof of concept and ongoing progress such as outsourcing final construct to Syngene.
Keep Gufic BioSciences Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.